Amicus Therapeutics (FOLD) News Today $8.16 -0.04 (-0.49%) Closing price 04:00 PM EasternExtended Trading$8.16 0.00 (0.00%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD)October 6 at 12:43 PM | finance.yahoo.comAmicus Therapeutics (NASDAQ:FOLD) Trading Up 6.5% - What's Next?October 1, 2025 | marketbeat.comBrokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $15.78September 25, 2025 | americanbankingnews.comAssenagon Asset Management S.A. Boosts Position in Amicus Therapeutics, Inc. $FOLDSeptember 23, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 22, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Wall Street ZenSeptember 20, 2025 | marketbeat.comNeedham Upgrades Amicus Therapeutics (FOLD)September 19, 2025 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up on Analyst UpgradeSeptember 19, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at Needham & Company LLCSeptember 19, 2025 | marketbeat.comVoya Investment Management LLC Sells 92,508 Shares of Amicus Therapeutics, Inc. $FOLDSeptember 19, 2025 | marketbeat.comAmicus upgraded to Buy at Needham banking on kidney disease therapySeptember 18, 2025 | msn.comPositive Outlook for Amicus Therapeutics Amid Legal Developments and Patent ConfidenceSeptember 17, 2025 | tipranks.comJefferies says Galafold summary judgment as expected, may facilitate settlementSeptember 16, 2025 | msn.comOsterweis Capital Management Inc. Takes Position in Amicus Therapeutics, Inc. $FOLDSeptember 14, 2025 | marketbeat.comCaxton Associates LLP Acquires New Position in Amicus Therapeutics, Inc. $FOLDSeptember 14, 2025 | marketbeat.comMillennium Management LLC Purchases 2,902,375 Shares of Amicus Therapeutics, Inc. $FOLDSeptember 14, 2025 | marketbeat.comComerica Bank Has $230,000 Stake in Amicus Therapeutics, Inc. $FOLDSeptember 11, 2025 | marketbeat.comAmicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comAmicus presents four-year data from PROPEL study of Pombiliti, OpfoldaSeptember 8, 2025 | msn.comAmicus Therapeutics Presents Long-Term Efficacy Data for Cipaglucosidase Alfa and Miglustat in Late-Onset Pompe Disease at ICIEM 2025September 8, 2025 | quiverquant.comQNew 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEMSeptember 8, 2025 | globenewswire.comParkman Healthcare Partners LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLDSeptember 8, 2025 | marketbeat.comAmicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for InvestorsSeptember 7, 2025 | msn.comCubist Systematic Strategies LLC Invests $4.51 Million in Amicus Therapeutics, Inc. $FOLDSeptember 7, 2025 | marketbeat.comTrexquant Investment LP Trims Stock Position in Amicus Therapeutics, Inc. $FOLDSeptember 7, 2025 | marketbeat.comBanque Transatlantique SA Takes $1.26 Million Position in Amicus Therapeutics, Inc. $FOLDSeptember 6, 2025 | marketbeat.com683 Capital Management LLC Invests $2.24 Million in Amicus Therapeutics, Inc. $FOLDSeptember 4, 2025 | marketbeat.comRedmile Group LLC Grows Stock Holdings in Amicus Therapeutics, Inc. $FOLDSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Has $34.88 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLDSeptember 4, 2025 | marketbeat.comAmicus Therapeutics, Inc. $FOLD Stock Position Lifted by Dark Forest Capital Management LPSeptember 4, 2025 | marketbeat.comAmicus Therapeutics, Inc. $FOLD Stock Position Lowered by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Grows Stock Holdings in Amicus Therapeutics, Inc. $FOLDSeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Reduces Holdings in Amicus Therapeutics, Inc. $FOLDSeptember 2, 2025 | marketbeat.com605,110 Shares in Amicus Therapeutics, Inc. $FOLD Bought by Kodai Capital Management LPSeptember 1, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Lowered to "Hold" Rating by Wall Street ZenSeptember 1, 2025 | marketbeat.comRussell Investments Group Ltd. Acquires 89,287 Shares of Amicus Therapeutics, Inc. $FOLDAugust 31, 2025 | marketbeat.comAmicus Therapeutics, Inc. (FOLD) Expands Pipeline With Rare Kidney Disease DrugAugust 30, 2025 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 30, 2025 | marketbeat.comIn NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are UnlawfulAugust 29, 2025 | globenewswire.comAmicus Therapeutics to Present at Upcoming Investor Conferences in September 2025August 29, 2025 | globenewswire.comJump Financial LLC Has $3.31 Million Holdings in Amicus Therapeutics, Inc. $FOLDAugust 28, 2025 | marketbeat.comAmicus Therapeutics, Inc. $FOLD Holdings Lifted by Capital Fund Management S.A.August 27, 2025 | marketbeat.comMultiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts StudentAugust 25, 2025 | businesswire.comCharles Schwab Investment Management Inc. Sells 95,723 Shares of Amicus Therapeutics, Inc. $FOLDAugust 24, 2025 | marketbeat.comAmicus Therapeutics, Inc. $FOLD Position Cut by Fox Run Management L.L.C.August 23, 2025 | marketbeat.comAmicus Therapeutics, Inc. $FOLD Shares Bought by Invesco Ltd.August 23, 2025 | marketbeat.com824,740 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Osterweis Capital Management Inc.August 22, 2025 | marketbeat.comWellington Management Group LLP Boosts Stake in Amicus Therapeutics, Inc. $FOLDAugust 22, 2025 | marketbeat.comIn NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against TrumpAugust 21, 2025 | globenewswire.comAberdeen Group plc Acquires 205,834 Shares of Amicus Therapeutics, Inc. $FOLDAugust 21, 2025 | marketbeat.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.740.53▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼27▲FOLD Articles Average Week Get the Latest News and Ratings for FOLD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies EXAS News MDGL News HALO News RGEN News ALKS News LGND News CLDX News MNKD News BCRX News NVAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
